Why BeOne Medicines AG’s (ONC) Stock Is Up 5.37%
As of Thursday, October 15, BeOne Medicines AG’s ONC share price has surged by 5.37%, which has investors questioning if this is right time to sell.Rosalio Madrigal
A+ Stock Grade Summary:
| VALUE: |
|
|
| GROWTH: |
|
|
| MOMENTUM: |
|
|
| EPS REVISIONS: |
|
|
| QUALITY: |
|
|
COMPANY SUMMARY
BeOne Medicines AG, an oncology company, engages in discovering and developing various treatments for cancer patients in the United States, China, Europe, and internationally. The company’s commercial stage products include BRUKINSA, a small molecule inhibitor of Bruton’s Tyrosine Kinase (BTK) for the treatment of various blood cancers; TEVIMBRA, an anti-PD-1 antibody immunotherapy for the treatment of various solid tumor and blood cancers; SYLVANT for the treatment of adult patients with multicentric castleman disease; BAITUOWEI for patients with BC in premenopausal and perimenopausal women, and cancer; and PARTRUVIX for the treatment of various solid tumors. Its clinical stage products comprise Sonrotoclax BGB-11417, a small molecule Bcl-2 inhibitor; BGB-16673, a BTK targeting chimeric degradation activation compound active against wild type and mutant BTK; BG-60366, an EGFR-targeted CDAC; BG-89894 (SYH2039), a MAT2A Inhibitor; BGB-58067, an MTA-Cooperative PRMT5 Inhibitor; BG-T187 and BG-C0902, an anti-EGFRxMET trispecific antibody; BGB-26808, a HPK-1 Inhibitor; BGB-C354, an anti-B7H3 ADC; Zanidatamab, a bispecific HER2-targeted antibody; BG-C137, an anti-FGFR2b ADC; BGB-53038, a Pan-KRAS Inhibitor; BGB-B2033, an anti-GPC3x4-1BB bispecific antibody; BGB-B3227, an anti-MUC1xCD16A bispecific antibody; BG-C477, an anti-CEAADC; BGB-43395, a CDK4 Inhibitor; BG-68501, a CDK2 Inhibitor; BG-C9074, an anti-B7H4 ADC; BGB-21447, a Bcl-2 Inhibitor; and BGB-45035, an IRAK4-targeted CDAC. It also has various preclinical programs. The company has agreements Amgen, BMS, Bio-Thera, EUSA Pharma, Luye Pharmaceutical, and Novartis. The company was formerly known as BeiGene, Ltd. and changed its name to BeOne Medicines AG in May 2025. The company has a agreement with U.S. government to expand access to innovative cancer medicines. BeOne Medicines AG was founded in 2010 and is based in Basel, Switzerland.
Commentary & Analysis
Why BeOne Medicines AG’s (ONC) Stock Is Down 5.83%
As of Thursday, October 08, BeOne Medicines AG’s ONC share price has dipped by 5.83%, which has investors questioning if this is right time to buy.Rosalio Madrigal
Why BeOne Medicines AG’s (ONC) Stock Is Down 6.37%
As of Thursday, October 08, BeOne Medicines AG’s ONC share price has dipped by 6.37%, which has investors questioning if this is right time to buy.Michael Rose
Why BeOne Medicines AG’s (ONC) Stock Is Down 5.67%
As of Thursday, October 08, BeOne Medicines AG’s ONC share price has dipped by 5.67%, which has investors questioning if this is right time to buy.Rosalio Madrigal
Which Is a Better Investment, BeOne Medicines AG or Twist Bioscience Corporation Stock?
Learn more about whether BeOne Medicines AG or Twist Bioscience Corporation is a better investment based on AAII's A+ Investor grades, which compare both companies' key financial metrics.Jenna Brashear
Financial Summary
| Share Statistics | ONC | Industry Median |
Percentile (All Stocks) |
|
| Market Cap (Mil) | $42,937.2 | $229.7 | 92% |
|
| Shares Out (Mil) | 115.8 | 53.4 | 65% |
|
| Institutional Ownership | 92.9% | 92.9% | 62% |
|
| Float (Mil) | 80.9 | 41.7 | 57% |
|
| Beta | 0.52 | 0.95 | 29% |
|
| Avg Daily Volume (000s) | 402 | 520 | 55% |
|
| Price Change (52-week) |
20.4% | 46.5% | 69% |
|
| Growth | ONC | Industry Median |
Percentile (All Stocks) |
|
| Sales (5yr) | 76.8% | 13.2% | 98% |
|
| Net Income (5yr) | 16.8% | (10.1%) | 67% |
|
| EPS (5yr) | 16.3% | 15.8% | 60 |
|
| Dividends (5yr) | 0.0% | 0.0% | 0% |
|
| Cash Flow (5yr) | 14.4% | (15.7%) | 71% |
|
| Estimates | Qtrly | Current Fiscal Year |
Next Fiscal Year |
|
| # of Estimates | 11 | 16 | 16 | |
| Current EPS | $1.882 | $7.641 | $10.446 | |
| Month Ago EPS | $1.819 | $7.602 | $10.318 | |
| # Rev Up | 1 | 1 | 1 | |
| # Rev Down | 0 | 0 | 0 | |
| Three Months Ago EPS | $1.714 | $6.474 | $9.682 | |
| Year/Year Chg | (9.5%) | 209.4% | 463.6% | |
| Financials | ONC | Industry Median |
Percentile (All Stocks) |
|
| Sales (TTM) (Mil) | $6,129 | $37 | 77% |
|
| Net Income (TTM) (Mil) | $656 | ($44) | 81% |
|
| EPS (TTM) | $5.914 | ($1.600) | 89% |
|
| Operating Cash Flow (TTM) (Mil) | $1,484 | ($33) | 85% |
|
| Net Cash Flow (TTM) (Mil) | $2,495 | $2 | 98% |
|
| Long-Term Debt (Q1) (Mil) | $1,747 | $4 | 73% |
|
| Enterprise Value (Q1) (Mil) | $36,843 | $175 | 90% |
|
| Valuation | ONC | Industry Median |
Percentile (All Stocks) |
|
| P/B | 8.25 | 2.17 | 89% |
|
| P/E | 67.6 | 20.1 | 90% |
|
| Dividend Yield | 0.0% | 0.0% | 0% |
|
| PEG (5yr hist) | 4.1 | 1.1 | 85% |
|
| Ratios | ONC | Industry Median |
Percentile (All Stocks) |
|
| Gross Margin | 88.9% | 66.5% | 93% |
|
| Net Margin | 10.7% | (75.9%) | 64% |
|
| ROA | 8.5% | (47.2%) | 83% |
|
| ROE | 14.7% | (53.5%) | 70% |
|
| Liabilities to Assets | 43.6% | 29.4% | 35% |
|
| F-Score | 7 | 2 | 82% |
|
Passing Stock Screens
As of 10/23/2026, from a list of 60 stock screening strategies,
GURU STRATEGY
Kirkpatrick Growth Screen
Factors: Momentum, Growth
Investing model outlined in Charles Kirkpatrick's book, Beat the Market: Invest by Knowing What Stocks to Buy and What Stocks to Sell.
| Performance Since Inception: | 14.3% |
| +/- S&P 500: | +6.8 |
